CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hangzhou Jiuyuan Gene Engineering Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hangzhou Jiuyuan Gene Engineering Co Ltd
Phone: +86 57186910099p:+86 57186910099 HANGZHOU, ZHJ  310018  China Ticker: 25662566
Business Summary
Hangzhou Jiuyuan Gene Engineering Co Ltd is a China-based company mainly engaged in the manufacturing and commercialization of biopharmaceutical products and medical devices. The Company focuses on therapeutic areas such as orthopedics, metabolic diseases, oncology, and hematology. The Company’s orthopedic products mainly comprise one drug-device combination product for bone repair under Guyoudao brand. The Company’s oncology products mainly comprise products for the treatment of neutropenia, chemotherapy-induced thrombocytopenia, nausea and vomiting induced by radiation therapy, chemotherapy or postoperatively, advanced breast cancer, and others. The Company’s hematology products mainly comprise generic small molecule drugs for the treatment of venous thromboembolic diseases. The Company is also involved in the development of metabolic disease drug.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023-----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
3842 Orthopedic, prosthetic, and surgical appliances and supplies

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, General Manager HangFu 61 1/1/2024 2/1/2000
Deputy General Manager, General Manager - Pharmacy services, Executive Director WeiZhou 49 1/1/2024 1/1/2014
Deputy General Manager, Chief Manager - Manufacturing Center HuiLi 52 3/1/2022 10/1/2017
9 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,467 (As of 6/30/2024)
Outstanding Shares: 245,398,800 (As of 6/30/2024)
Stock Exchange: HKG
Fax Number: +86 57186911688


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 22, 2024